Seagen targets Daiichi in cancer drug suit

US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

18 November 2020 Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

More on this story

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

More on this story

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen